With prophylaxis above $300,000 a year and no cure, US payers manage HAE almost entirely through specialty-tier utilization management — and ICER's value-based benchmarks sit well below list price.
HAE prophylaxis is one of the most expensive US drug categories, routinely more than $300,000 per patient per year, which keeps utilization management, not clinical debate, at the centre of access. Agents sit on the specialty tier, and prior authorization is near-universal: representative criteria require confirmation of the HAE diagnosis (low C4 with C1-INH antigenic and functional testing), an allergist or immunologist prescriber, documented failure or intolerance of prior therapy such as attenuated androgens or antifibrinolytics, and laboratory confirmation before a targeted prophylactic agent is approved. Benefit routing splits the class: subcutaneous antibodies and C1-inhibitor replacement run through the medical benefit, while oral berotralstat runs through the pharmacy benefit — creating an out-of-pocket asymmetry that can favour the injectable route for some Medicare patients.
ICER has assessed HAE prophylaxis twice, in a 2018 Final Evidence Report and a 2021 real-world-evidence update, and in both cases set value-based price benchmarks below list, giving payers a published anchor for rebate negotiation on lanadelumab and C1-inhibitor replacement (the two agents ICER assessed). Payers also police the prophylaxis/on-demand boundary: coverage policies commonly restrict concurrent use of a long-term prophylactic and routine on-demand dosing to the acute-rescue setting, so patients cannot stack agents. The 2025 entrants (garadacimab, donidalorsen and the first oral on-demand agent sebetralstat) arrive without a dedicated ICER review, leaving their value positioning to be argued against the existing benchmark set.
US HAE agent payer view — routing, PA criteria and access signal
| Drug (Brand / INN) | Route / Benefit | Representative PA Criteria | Cost / Value Signal | ICER / Access Note |
|---|---|---|---|---|
| Takhzyro (lanadelumab) | SC · medical benefit | HAE dx confirmed (C4 / C1-INH); allergist/immunologist; prior androgen or antifibrinolytic failure | ~87% attack reduction vs placebo (HELP); >$300K/yr class cost | Assessed by ICER 2018/2021; value-based benchmark below list price |
| Orladeyo (berotralstat) | Oral · pharmacy benefit | Same dx + specialist + prior-therapy-failure criteria; oral routing creates OOP differential | ~44% attack reduction vs placebo (APeX-2); oral convenience trade-off | No dedicated ICER review; often positioned as oral option before injectable escalation |
| Haegarda (C1-INH, SC) | SC · medical benefit | HAE dx confirmed; specialist prescriber; documented attack frequency; home-infusion eligible | COMPACT ≈ 90% response; longest safety record in class | Assessed by ICER 2018; value-based benchmark below list price |
| Andembry (garadacimab) | SC monthly · medical benefit | Same specialty-tier PA framework; new agent — criteria forming at plans | ~87% attack reduction vs placebo (VANGUARD) | No dedicated ICER review — positioned against existing benchmark set |
| Dawnzera (donidalorsen) | SC q4–8 wk · medical benefit | Same specialty-tier PA framework; extended dosing interval a formulary talking point | 81% lower attack rate vs placebo (OASIS-HAE) | No dedicated ICER review at launch; value case argued vs incumbents |
| Ekterly (sebetralstat) | Oral on-demand · pharmacy benefit | On-demand rescue coverage; concurrent-use rules limit stacking with prophylaxis | First oral on-demand; 1.6 h median time to relief (KONFIDENT) | No dedicated ICER review; addresses parenteral-delay unmet need |
Sources: FDA Drugs@FDA / FDA Orphan Drug database (approval status); HELP, JAMA 2018 (PMID 30480729); APeX-2, J Allergy Clin Immunol 2020 (PMID 33098856); COMPACT, NEJM 2017 (PMID 28328347); VANGUARD, Lancet 2023 (PMID 36868261); OASIS-HAE, NEJM 2024 (PMID 38819395); KONFIDENT, NEJM 2024 (PMID 38819658); ICER 2018 Final Evidence Report and 2021 real-world-evidence update; Prime Therapeutics HAE cost analyses; US commercial payer coverage policies.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- Representative PA criteria: diagnosis confirmation (C4 / C1-INH antigenic and functional), allergist/immunologist prescriber requirement, prior androgen or antifibrinolytic failure, and lab confirmation
- agent-by-agent variation
Delivers
- ICER 2018 evidence report and 2021 RWE update findings
- value-based benchmark discounts vs list price
- how garadacimab, donidalorsen and sebetralstat sit against the existing benchmark set
Delivers
- Medical vs pharmacy benefit routing (injectable vs oral) and the OOP asymmetry
- coverage rules restricting concurrent prophylaxis and on-demand use
- formulary posture given >$300K/patient/yr cost
Custom assessment delivered in 72 hours.
Commission This AssessmentWhat's inside
- Why HAE prophylaxis, routinely priced above $300,000 per patient per year, keeps utilization management at the center of access.
- How near-universal specialty-tier prior authorization requires diagnosis confirmation and a documented prior-therapy failure.
- Why representative PA criteria require an allergist or immunologist prescriber plus documented failure of attenuated androgens or antifibrinolytics.
- How oral berotralstat's pharmacy-benefit routing differs from the medical-benefit routing of injectable prophylactic agents.
- How ICER's 2018 Final Evidence Report and 2021 real-world-evidence update set value-based price benchmarks below list.
- Why lanadelumab and C1-inhibitor replacement, the two agents ICER assessed, anchor payer rebate negotiation today.
- Why subcutaneous antibodies and C1-inhibitor replacement route through the medical benefit while oral berotralstat runs through pharmacy.
- How this split creates an out-of-pocket asymmetry that can favor the injectable route for some Medicare patients.
- Why coverage policies commonly restrict concurrent use of a long-term prophylactic and routine on-demand dosing.
- How payers reserve on-demand agents for acute rescue only, preventing patients from stacking prophylactic and rescue therapies.
- Why garadacimab, donidalorsen and sebetralstat, the 2025 entrants, arrive without a dedicated ICER review.
- How sebetralstat's status as the first oral on-demand agent leaves its value positioning to be argued against existing benchmarks.
Included with every brief
How AXLRx builds this assessment
Prepared by MoatRx analysts.
US Hereditary Angioedema Payer & HTA is built from HTA body publications, cost analyses, regulatory records and live payer policy documents — not secondary summaries or market-research reports. Cost-effectiveness findings are drawn from the ICER evidence reports; efficacy anchors are tied to the primary trial publications; and prior-authorization criteria are drawn from current US commercial payer coverage policies. Any figure that cannot be sourced to a live record does not ship.
Key sources: the ICER 2018 Final Evidence Report on HAE prophylaxis and the 2021 real-world-evidence update; Prime Therapeutics HAE cost-of-care analyses; FDA Drugs@FDA and the FDA Orphan Drug database for approval status; primary trials HELP (PMID 30480729), APeX-2 (PMID 33098856) and COMPACT (PMID 28328347); and current US commercial payer specialty-pharmacy coverage policies.
- HAE prophylaxis cost (>$300K per patient per year) attributed to Prime Therapeutics / ICER published cost analyses
- Cost-effectiveness and value-based benchmark findings verified against the ICER 2018 Final Evidence Report and 2021 real-world-evidence update
- Efficacy anchors verified against primary trials: HELP (PMID 30480729), APeX-2 (PMID 33098856), COMPACT (PMID 28328347)
- FDA approval status verified against FDA Drugs@FDA and the FDA Orphan Drug database
- Specialty-tier PA criteria and concurrent-agent rules drawn from current US commercial payer coverage policy documents
Frequently asked questions
Commission this assessment
AXLRx US Hereditary Angioedema Payer & HTA is built for market access, HEOR, and pricing teams navigating specialty-tier PA, ICER positioning and the benefit-routing asymmetry in the US HAE market. Custom assessment in 72 hours.
Specify indication, payer focus (PA criteria, ICER, benefit routing), and commercial question.
AXLRx analyst confirms payer scope, comparators, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.